TrimRX | CagriSema How It Works: Mechanism of Action Explained

Introduction

CagriSema is Novo Nordisk’s investigational weight management drug that combines two hormones in a single weekly injection. The first is semaglutide, the GLP-1 receptor agonist already familiar from Ozempic®, Wegovy®, and Rybelsus®. The second is cagrilintide, a long-acting analog of amylin, a hormone made in the pancreas that controls how full you feel after eating. The combination targets two separate appetite pathways at once.

The drug is in late-stage development. The REDEFINE phase 3 program tested CagriSema in adults with obesity (REDEFINE 1), in adults with overweight or obesity plus type 2 diabetes (REDEFINE 2), and in cardiovascular outcomes (REDEFINE 3). Top-line data from REDEFINE 1, announced in December 2024, showed mean weight loss of about 22.7% at 68 weeks at the highest dose (2.4 mg semaglutide plus 2.4 mg cagrilintide), the strongest weight loss reported for any pharmacotherapy at that endpoint.

The mechanism story matters because amylin is a hormone we haven’t used much in weight management before. Pramlintide (Symlin) is an older amylin analog used for diabetes, but the dosing is inconvenient and the weight loss modest. Cagrilintide is designed for weekly dosing alongside semaglutide, and the combination produces additive appetite suppression that neither agent achieves alone.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Amylin and Why Is Cagrilintide Different From Semaglutide?

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. After a meal, amylin enters the bloodstream alongside insulin and acts on amylin receptors in the brain (specifically the area postrema). The signal slows gastric emptying, suppresses glucagon secretion, and creates a sense of fullness that limits further eating. Native amylin has a half-life of about 13 minutes, which is too short for therapeutic use.

Quick Answer: CagriSema = semaglutide (GLP-1 agonist) + cagrilintide (amylin analog), once weekly subcutaneous injection

Cagrilintide is a chemically modified amylin analog with a 7-day half-life. The structural changes (fatty acid acylation and amino acid substitutions) allow once-weekly subcutaneous dosing similar to semaglutide. The drug binds amylin and calcitonin receptors, with calcitonin receptor activation contributing to satiety effects.

GLP-1 receptor activation by semaglutide and amylin receptor activation by cagrilintide produce overlapping but not identical effects. Both reduce appetite, both slow gastric emptying, both improve glycemic control. The hypothalamic and brainstem pathways involved are different. Combining the two produces additive (not just redundant) appetite suppression, which is the clinical signal in REDEFINE 1.

How Does the Combination Produce More Weight Loss Than Semaglutide Alone?

The data from REDEFINE 1 and earlier phase 2 studies (Enebo et al. 2021) suggests the combination produces 5-7 percentage points more weight loss than semaglutide monotherapy at similar timepoints. Semaglutide 2.4 mg in STEP 1 (Wilding et al. 2021 NEJM) produced 14.9% weight loss at 68 weeks. CagriSema in REDEFINE 1 produced about 22.7% at 68 weeks. The cagrilintide contribution is real and additive.

The mechanism appears to be complementary pathways for satiety and reduced energy intake. GLP-1 acts strongly in the hypothalamus and brainstem to reduce appetite. Amylin acts in the area postrema and other brain regions. The two receptors are on different neurons, and stimulating both creates a stronger overall satiety signal than maximal stimulation of either alone.

Glycemic effects are also synergistic. Both drugs improve insulin sensitivity, slow gastric emptying, and reduce postprandial glucose spikes. For patients with type 2 diabetes (REDEFINE 2), A1c reductions matched or exceeded what semaglutide produces alone.

What Does the Dual Receptor Activation Do in the Brain?

The brain regions involved in appetite control include the hypothalamus (arcuate nucleus, paraventricular nucleus, lateral hypothalamic area), the brainstem (nucleus tractus solitarius, area postrema), and reward centers (nucleus accumbens, ventral tegmental area). GLP-1 receptors are widely expressed in these regions. Amylin receptors are concentrated in the area postrema and adjacent structures.

When both receptor systems are activated simultaneously, the result is broad activation of satiety neurons and broad suppression of feeding neurons. Patients on CagriSema typically describe reduced food cravings, smaller portion sizes, and meaningful loss of interest in hyperpalatable foods. The hedonic side of eating (reward, pleasure from food) is more affected than with semaglutide alone.

This isn’t unique to CagriSema. Tirzepatide’s dual GIP/GLP-1 mechanism produces similar broad receptor activation and the strongest weight loss reported in single-agent therapy (20.9% in SURMOUNT-1). The pattern across these dual-mechanism drugs is consistent: stimulating multiple appetite pathways simultaneously produces stronger and more durable weight loss than single-pathway drugs.

How Is CagriSema Dosed and Delivered?

CagriSema is delivered as a once-weekly subcutaneous injection, using a fixed-ratio combination of semaglutide and cagrilintide in a single pen device. The expected commercial formulation contains both molecules in one solution, dosed together. Titration starts at lower combined doses and works up to maintenance over several months.

The expected maintenance dose is 2.4 mg semaglutide plus 2.4 mg cagrilintide, matching the doses used in REDEFINE trials. Earlier titration steps use proportionally lower amounts of each component. This is operationally similar to Zepbound®’s titration schedule (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) but with two active ingredients moving together.

Injection technique matches other subcutaneous GLP-1 drugs: abdomen, thigh, or upper arm. Pen needles are 4-6 mm in length. Injection should rotate between sites to avoid lipohypertrophy. Patients self-administer at home after initial training, similar to Wegovy and Ozempic.

What Does REDEFINE 1 Data Actually Show?

REDEFINE 1 enrolled approximately 3,400 adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related comorbidity. The trial randomized 4:1 to CagriSema or placebo, with lifestyle counseling for all participants. Treatment duration was 68 weeks at the highest tolerated dose.

Mean weight loss in the CagriSema group was 22.7%, compared with about 2.3% in the placebo group. Approximately 40% of CagriSema patients achieved >=25% weight loss; about 30% achieved >=20%; about 80% achieved >=10%. These response rates are stronger than any prior weight management trial for any pharmacotherapy.

A1c improvement, blood pressure reduction, lipid changes, and inflammatory markers (high-sensitivity CRP) all improved. Cardiovascular risk markers shifted favorably, though hard MACE outcomes will come from REDEFINE 3. The safety profile matched the broader GLP-1 class with predominantly mild-to-moderate GI side effects.

What Does REDEFINE 2 Show for Diabetes Patients?

REDEFINE 2 tested CagriSema in adults with type 2 diabetes plus overweight or obesity. The trial enrolled about 1,200 patients on background metformin with A1c 7.0-10.0%. Treatment duration was 68 weeks at maximum tolerated dose.

Top-line results announced in 2025 showed about 13.7% mean weight loss in the CagriSema group versus about 3.4% in placebo. The weight loss was somewhat lower than REDEFINE 1 (22.7%), which is consistent with the general pattern that patients with diabetes lose less weight on GLP-1 therapy than patients without diabetes. A1c reduction was approximately 1.8 percentage points, similar to or slightly better than semaglutide monotherapy in SUSTAIN trials.

Hypoglycemia rates were low because semaglutide doesn’t cause hypoglycemia at standard doses unless combined with insulin or sulfonylureas. Patients on background metformin alone tolerated the drug well from a glycemic perspective. The combination did produce more GI side effects than placebo, mirroring the dose-response seen with monotherapy GLP-1.

How Does CagriSema Compare to Tirzepatide?

Both drugs use dual-mechanism approaches to maximize weight loss. Tirzepatide (Zepbound, Mounjaro®) combines GLP-1 and GIP receptor activation in a single peptide molecule. CagriSema combines GLP-1 and amylin receptor activation through two separate molecules in one injection.

Head-to-head trial data isn’t published. Cross-trial comparison (which has limitations) suggests:

SURMOUNT-1 (tirzepatide 15 mg): 20.9% weight loss at 72 weeks
REDEFINE 1 (CagriSema highest dose): 22.7% weight loss at 68 weeks

The CagriSema number is slightly higher, but the trial designs and patient populations differ in ways that prevent direct comparison. A head-to-head trial would settle the question. As of 2026, no such trial has been announced.

For patients and prescribers, the practical difference is dosing complexity. Tirzepatide is a single peptide with simple titration. CagriSema is a two-drug combination that may require more careful initial titration to manage side effects from both components.

Key Takeaway: Dual mechanism: GLP-1 receptor and amylin receptor activation, with complementary appetite signals

What Patients Are Most Likely to Benefit?

Three patient profiles fit CagriSema based on the trial data:

First, patients with severe obesity (BMI >=40) who need maximum pharmacologic weight loss to reach their goals. The 22.7% mean and ~40% achieving >=25% weight loss in REDEFINE 1 are the strongest results in pharmacotherapy. Patients targeting bariatric-surgery-like outcomes have a reason to consider CagriSema once approved.

Second, patients who plateaued on semaglutide monotherapy and want additional weight loss. The cagrilintide component provides a different appetite pathway than what semaglutide alone activates. Conversion from semaglutide to CagriSema is straightforward once approved.

Third, patients with type 2 diabetes plus obesity who want strong glycemic and weight benefit in a single weekly injection. REDEFINE 2 supports this use. Coverage may be more accessible through diabetes indications than through obesity-only indications.

What Does Cagrilintide Do That Semaglutide Doesn’t?

Cagrilintide activates amylin receptors that semaglutide doesn’t touch. The two key amylin receptor sites in humans are AMY1R (calcitonin receptor plus RAMP1) and AMY3R (calcitonin receptor plus RAMP3). Both are concentrated in the area postrema, a brainstem region without a blood-brain barrier, which makes it a sensitive sensor for circulating hormones.

When cagrilintide binds these receptors, calcium signaling within the neurons increases and downstream pathways produce satiety and slowed gastric emptying. The signal is integrated with GLP-1 receptor signaling at a network level, even though the two hormones act on separate neurons. The combined effect on food intake is larger than either alone.

Cagrilintide also has modest effects on calcitonin receptor activity in bone and kidney, though clinical implications appear minimal. The drug is highly selective for amylin pathways at therapeutic doses. Long-term safety data through phase 3 is reassuring but the post-approval safety database will grow over 5-10 years.

What Is the Rationale for Combining Instead of Using Cagrilintide Alone?

Cagrilintide monotherapy in phase 2 trials produced modest weight loss, around 10% at high doses over 26 weeks. That’s similar to liraglutide monotherapy (8% at 56 weeks in SCALE) but well below semaglutide 2.4 mg (14.9% in STEP 1). Amylin alone isn’t competitive with modern GLP-1 monotherapy.

The combination strategy is what makes cagrilintide commercially viable. By pairing it with semaglutide, Novo Nordisk captures the strong semaglutide weight loss baseline and adds the amylin boost on top. The combination is greater than the sum of its parts in the published data.

This is the same logic that drove tirzepatide’s dual GIP/GLP-1 development. GIP alone isn’t a useful weight loss drug, but combined with GLP-1 in a single peptide, the result is exceptional efficacy. CagriSema applies the combination logic with two separate molecules rather than one fused peptide.

How Does the Body Respond to Long-term Amylin Signaling?

One concern with any chronic appetite-suppressing therapy is receptor desensitization. The body adapts. For semaglutide, real-world data through several years of use shows persistent efficacy when patients stay on therapy, with weight regain occurring after stopping. The amylin receptor system has a similar adaptation pattern based on cagrilintide phase 2 data: efficacy continues with chronic dosing.

The body does adapt other hormones in response to weight loss. Leptin levels drop. Ghrelin rises. Resting energy expenditure decreases. These changes are not specific to CagriSema; they happen with any sustained weight loss, including bariatric surgery and dietary intervention. The drug doesn’t override these adaptive changes, which is why weight regain is common after stopping any GLP-1 or combination therapy.

For practical patient management, this means continued therapy is part of weight maintenance. The drug isn’t a one-time intervention. Patients should plan on multi-year therapy if they want to sustain the weight loss achieved during titration and maintenance phases. TrimRx’s clinical model emphasizes ongoing support during chronic therapy rather than single-course treatment.

What Does the Metabolic Profile Look Like Beyond Weight?

CagriSema affects metabolic markers beyond weight in ways that match other GLP-1 therapies. Fasting glucose drops. A1c improves by approximately 1-2 percentage points. Triglycerides decrease by 20-30%. LDL cholesterol drops modestly. Blood pressure falls by 4-7 mm Hg systolic in trials. Inflammatory markers like hs-CRP decrease meaningfully.

For patients with metabolic syndrome (the cluster of central obesity, hyperglycemia, hypertension, dyslipidemia, and insulin resistance), CagriSema addresses multiple components simultaneously. This is one of the reasons GLP-1 class drugs have moved from diabetes-only into broader cardiometabolic indications. The mechanism affects whole-body metabolism, not just appetite.

REDEFINE 3, the cardiovascular outcomes trial, will test whether these favorable metabolic shifts translate to actual reductions in heart attack, stroke, and CV death. The trial is ongoing with expected readout 2027-2028. Based on the broader GLP-1 class showing CV benefit (SELECT, FLOW, SURPASS-CVOT, STEP-HFpEF), the CagriSema CVOT is likely to show favorable results.

Bottom line: Not yet FDA-approved; regulatory submission expected 2026

FAQ

When Will CagriSema Be Available?

Novo Nordisk has signaled regulatory submission in 2026 based on REDEFINE 1 and 2 data. Expected FDA approval timeline is late 2026 to early 2027 for obesity. Diabetes indication submission and approval may follow on a similar timeline.

How Does CagriSema Differ From Semaglutide Alone?

CagriSema adds cagrilintide, an amylin analog, to semaglutide in a single weekly injection. The amylin component provides additional appetite suppression through a separate receptor pathway, producing roughly 5-7 percentage points more weight loss than semaglutide alone at the same timepoint.

Will CagriSema Be Covered by Insurance?

Coverage will likely follow Wegovy precedent: covered by some commercial plans for obesity, not covered by Medicare for weight loss, and covered by Medicare Part D for the diabetes indication once approved. Prior authorization will likely be standard.

What Are the Most Common Side Effects of CagriSema?

Nausea, vomiting, diarrhea, constipation, and reduced appetite. The pattern matches semaglutide monotherapy but with somewhat higher rates because two appetite-suppressing mechanisms operate simultaneously. Most events resolve within 4-8 weeks of titration.

Can I Get Compounded CagriSema?

No. Compounded versions of CagriSema are not available because the drug isn’t approved and the combination is not on FDA’s approved-active-ingredient list. Anything sold online as “CagriSema” before approval should be treated as counterfeit.

How Does the Amylin Receptor Differ From the GLP-1 Receptor?

Both are G-protein-coupled receptors expressed in the brain and gut. GLP-1 receptors are widely distributed in the hypothalamus, brainstem, pancreas, and elsewhere. Amylin receptors are concentrated in the area postrema and adjacent brainstem regions. The two receptors are pharmacologically distinct, though their downstream effects on appetite and gastric motility overlap.

Will CagriSema Replace Semaglutide and Tirzepatide?

Not entirely. CagriSema will likely capture market share from patients who want maximum weight loss in a weekly injection. Patients who do well on existing options may stay on those drugs. The GLP-1 category is expanding rather than consolidating.

Can Patients with Diabetes Use CagriSema for Diabetes Management?

REDEFINE 2 tested this specifically and showed approximately 1.8 percentage point A1c reduction plus 13.7% weight loss. Once approved, CagriSema will likely have a diabetes indication. For patients with both diabetes and obesity, the combination provides simultaneous benefit on both conditions.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

CagriSema How It Works: Mechanism of Action Explained

Table of Contents